Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.

Blood - 26 Dec 2024

Lachowiez Curtis A, Ravikumar Vishvaas I, Othman Jad, O'Nions Jenny, Peters Daniel T, McMahon Christine, Swords Ronan, Cook Rachel, Saultz Jennifer N, Tyner Jeffrey W, Dillon Richard, Zeidner Joshua F, Pollyea Daniel A

Abstract excerpt

ABSTRACT: The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.

Topics

Join the communities discussing this publication.

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Bridged Bicyclo Compounds, Heterocyclic
Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Risk Assessment

Source

Identifiers

PMID: 39486083
DOI: 10.1182/blood.2024026925

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.PMID 39486083Read ↗

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxSemantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Semantic proximity Read ↗

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.Semantic proximity Read ↗

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating AgentSemantic proximity Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.Semantic proximity Read ↗

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.